Description
Created On: 2020-07-15
Record Count: 4
Primary Industries
- Drug Discovery
- Therapeutic
- Software
- Medical Info
- Drugs
- Assay
- Disease
- DNA
- Genome
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 250927
IPSCIO Record ID: 222558
For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.
For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows: the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.
For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.
Product means any Agreement Product or Licensees Product.
Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.
Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.
Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.
Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'
IPSCIO Record ID: 203310
Licensor will generate and deliver to Licensee two complete copies of a library consisting of three hundred fifty thousand (350,000) mouse embryonic stem cell clones with Selected Mutations, each identified by DNA sequence of its genomic integration site, the OmniBank II Library. Subject to the terms of this Agreement, Licensor will use Diligent Efforts to generate and deliver the OmniBank II Library in accordance with the schedule set forth in the Development Plan.
Licensor grants to Licensee the non-transferable, non-exclusive right under Licensors rights in the Cre-Lox Patents to use, breed and cross-breed Mutant Mice and Progeny that contain one or more lox sites in their genome (Lox Mice), at the internal research facilities of Licensee, solely for research purposes.
Licensor grants to Licensee a worldwide, non-exclusive right and license to use the Bioinformatics Software, under the copyrights and know-how Controlled by Licensor with respect thereto. Licensee shall have the right under the foregoing license to custom configure the Bioinformatics Software for its internal use.
The Bioinformatics Software means the software for the management and analysis of data relating to the OmniBank II Library and the production, genotyping and phenotypic analysis of knockout mice.
The library, constructed using Licensor's proprietary mouse gene knockout technology, will enable a researcher to develop a mouse that has a specific gene removed or “knocked-out.†The function of that gene can then be studied by comparing the knockout mouse to a normal mouse. Approximately 99 percent of human genes have a mouse counterpart, and research using this technology may lead to the development of drugs for a wide variety of human and animal diseases, including diabetes and obesity, infectious disease, cancer and heart disease. Institute researchers will have certain rights to utilize Lexicon’s patented gene targeting technologies. In addition, Licensor will equip the Institute with the bioinformatics software required for the management and analysis of data relating to the library.
IPSCIO Record ID: 203543
(a) an exclusive right and license under the Technology, exclusive even as to Licensor, to use, have used, sell, have sold, import, have imported, further develop, improve and otherwise exploit in any manner the Licensees Activated Receptor, for the purpose of identification of CART Identified Compound(s) in the Territory, and
(b) an exclusive right and license under the Technology, exclusive even as to Licensor, to develop, manufacture, have manufactured, promote, market, sell, distribute and, license CART Identified Compound(s) and/or Drug Product(s) in the Territory.
Drug product means a therapeutic product comprising a CART Identified Compound.
Licensees Activated Receptor means a Licensee Selected GPCR to which the Licensor Activation Technology has been applied.
G Protein Coupled Receptor and GPCR means an Endogenous cell-surface receptor defined by having three (3) intracellular loops, three (3) extracellular loops, an amino terminus and a carboxy terminus.
Licensor is an emerging biopharmaceutical company focused principally on discovering drugs that act on an important class of drug targets called G protein-coupled receptors, or GPCRs. Licensor has developed a technology called Constitutively Activated Receptor Technology, or CART, that can be applied to GPCRs and other classes of receptors to identify drug leads. Licensor believesthat CART is a more efficient drug discovery technique than traditional drug discovery techniques.